Glycemic Targeting

The 7-mg and 14-mg oral semaglutide tablets are now indicated to reduce the risk of major adverse cardiovascular events in adults with diabetes.

Melanie T. Turk, PhD, RN, discusses her study on nationwide challenges program suppliers face in implementing the Medicare Diabetes Prevention Program (MDPP).

A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

This study describes the current opportunities and obstacles associated with Medicare Diabetes Prevention Program implementation from the novel perspective of program suppliers across the US.

A RAND report shows Medicare’s 3-year insulin savings model cut costs, improved access for beneficiaries, and offers lessons for future drug pricing reforms.